FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076334524> ?p ?o ?g. }

• W2076334524 endingPage "614" @default.
• W2076334524 startingPage "607" @default.
• W2076334524 abstract "Purpose: In a series of trials, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV) have been identified as effective treatments for Hodgkin’s disease. We compared these regimens as initial chemotherapy for Hodgkin’s disease. Patients and Methods: Adult patients (N = 856) with advanced Hodgkin’s disease were randomly assigned to treatment with ABVD or MOPP/ABV. The major end points were failure-free and overall survival, life-threatening acute toxicities, and serious long-term toxicities, including cardiomyopathy, pulmonary toxicity, myelodysplastic syndromes (MDS), and secondary malignancies. Results: The rates of complete remission (76% v 80%, P = .16), failure-free survival at 5 years (63% v 66%, P = .42), and overall survival at 5 years (82% v 81%, P = .82) were similar for ABVD and MOPP/ABV, respectively. Clinically significant acute pulmonary and hematologic toxicity were more common with MOPP/ABV (P = .060 and .001, respectively). There was no difference in cardiac toxicity. There were 24 deaths attributed to initial treatment: nine with ABVD and 15 with MOPP/ABV (P = .057). There have been 18 second malignancies associated with ABVD and 28 associated with MOPP/ABV (P = .13). Thirteen patients have developed MDS or acute leukemia: 11 were initially treated with MOPP/ABV, and two were initially treated with ABVD but subsequently received MOPP-containing regimens and radiotherapy before developing leukemia (P = .011). Conclusion: ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin’s disease. MOPP/ABV is associated with a greater incidence of acute toxicity, MDS, and leukemia. ABVD should be considered the standard regimen for treatment of advanced Hodgkin’s disease." @default.
• W2076334524 created "2016-06-24" @default.
• W2076334524 creator A5009574158 @default.
• W2076334524 creator A5021842242 @default.
• W2076334524 creator A5022658681 @default.
• W2076334524 creator A5062378578 @default.
• W2076334524 creator A5068867603 @default.
• W2076334524 creator A5069340619 @default.
• W2076334524 creator A5070128429 @default.
• W2076334524 creator A5074153446 @default.
• W2076334524 date "2003-02-15" @default.
• W2076334524 modified "2023-10-16" @default.
• W2076334524 title "Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup Trial" @default.
• W2076334524 cites W1827683443 @default.
• W2076334524 cites W1941328144 @default.
• W2076334524 cites W1942009620 @default.
• W2076334524 cites W1942259007 @default.
• W2076334524 cites W1990639292 @default.
• W2076334524 cites W2041214084 @default.
• W2076334524 cites W2041629407 @default.
• W2076334524 cites W2059707463 @default.
• W2076334524 cites W2156906636 @default.
• W2076334524 cites W2165308914 @default.
• W2076334524 cites W2229695843 @default.
• W2076334524 cites W2320109738 @default.
• W2076334524 cites W2321358810 @default.
• W2076334524 cites W2328676772 @default.
• W2076334524 cites W2338057729 @default.
• W2076334524 cites W2340198921 @default.
• W2076334524 cites W2341591060 @default.
• W2076334524 cites W4242128403 @default.
• W2076334524 cites W4246614500 @default.
• W2076334524 doi "https://doi.org/10.1200/jco.2003.12.086" @default.
• W2076334524 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12586796" @default.
• W2076334524 hasPublicationYear "2003" @default.
• W2076334524 type Work @default.
• W2076334524 sameAs 2076334524 @default.
• W2076334524 citedByCount "438" @default.
• W2076334524 countsByYear W20763345242012 @default.
• W2076334524 countsByYear W20763345242013 @default.
• W2076334524 countsByYear W20763345242014 @default.
• W2076334524 countsByYear W20763345242015 @default.
• W2076334524 countsByYear W20763345242016 @default.
• W2076334524 countsByYear W20763345242017 @default.
• W2076334524 countsByYear W20763345242018 @default.
• W2076334524 countsByYear W20763345242019 @default.
• W2076334524 countsByYear W20763345242020 @default.
• W2076334524 countsByYear W20763345242021 @default.
• W2076334524 countsByYear W20763345242022 @default.
• W2076334524 countsByYear W20763345242023 @default.
• W2076334524 crossrefType "journal-article" @default.
• W2076334524 hasAuthorship W2076334524A5009574158 @default.
• W2076334524 hasAuthorship W2076334524A5021842242 @default.
• W2076334524 hasAuthorship W2076334524A5022658681 @default.
• W2076334524 hasAuthorship W2076334524A5062378578 @default.
• W2076334524 hasAuthorship W2076334524A5068867603 @default.
• W2076334524 hasAuthorship W2076334524A5069340619 @default.
• W2076334524 hasAuthorship W2076334524A5070128429 @default.
• W2076334524 hasAuthorship W2076334524A5074153446 @default.
• W2076334524 hasConcept C126322002 @default.
• W2076334524 hasConcept C141071460 @default.
• W2076334524 hasConcept C143998085 @default.
• W2076334524 hasConcept C2776305933 @default.
• W2076334524 hasConcept C2776694085 @default.
• W2076334524 hasConcept C2776755627 @default.
• W2076334524 hasConcept C2777132456 @default.
• W2076334524 hasConcept C2778720950 @default.
• W2076334524 hasConcept C2779112685 @default.
• W2076334524 hasConcept C2779429289 @default.
• W2076334524 hasConcept C2780964509 @default.
• W2076334524 hasConcept C71924100 @default.
• W2076334524 hasConcept C90924648 @default.
• W2076334524 hasConceptScore W2076334524C126322002 @default.
• W2076334524 hasConceptScore W2076334524C141071460 @default.
• W2076334524 hasConceptScore W2076334524C143998085 @default.
• W2076334524 hasConceptScore W2076334524C2776305933 @default.
• W2076334524 hasConceptScore W2076334524C2776694085 @default.
• W2076334524 hasConceptScore W2076334524C2776755627 @default.
• W2076334524 hasConceptScore W2076334524C2777132456 @default.
• W2076334524 hasConceptScore W2076334524C2778720950 @default.
• W2076334524 hasConceptScore W2076334524C2779112685 @default.
• W2076334524 hasConceptScore W2076334524C2779429289 @default.
• W2076334524 hasConceptScore W2076334524C2780964509 @default.
• W2076334524 hasConceptScore W2076334524C71924100 @default.
• W2076334524 hasConceptScore W2076334524C90924648 @default.
• W2076334524 hasIssue "4" @default.
• W2076334524 hasLocation W20763345241 @default.
• W2076334524 hasLocation W20763345242 @default.
• W2076334524 hasOpenAccess W2076334524 @default.
• W2076334524 hasPrimaryLocation W20763345241 @default.
• W2076334524 hasRelatedWork W141689507 @default.
• W2076334524 hasRelatedWork W1827095708 @default.
• W2076334524 hasRelatedWork W2019922408 @default.
• W2076334524 hasRelatedWork W2055310422 @default.
• W2076334524 hasRelatedWork W2058793701 @default.
• W2076334524 hasRelatedWork W2077424156 @default.
• W2076334524 hasRelatedWork W2132492509 @default.
• W2076334524 hasRelatedWork W2171380046 @default.

• next